Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Results with Loxo-305 could justify Lilly’s acquisition of Loxo, but its inventor, the UK’s Redx, can just read ‘em and weep.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.